Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1995-5-3
|
pubmed:abstractText |
Interleukin 3 (IL-3) is a hematopoietic growth factor with a pronounced thrombopoietic activity as well as a broad spectrum of activities on multipotent, committed and mature cells of different lineages. Available for clinical trials since 1989, IL-3 has been used in well over two thousand patients. In numerous phase I-II clinical trials, the tolerability profile and the various biologic activities have been defined, and ongoing phase III trials will finally establish its clinical relevance. Doses between 2.5 and 10 micrograms/kg/d given subcutaneously are well tolerated, cause low grade fever, occasional flu-like symptoms and headache. At these doses IL-3 enhances platelet and neutrophil recovery after cycles of myelotoxic chemotherapy, resulting in better adherence to the planned chemotherapy doses and schedules and a decrease in the need for platelet transfusions. Accelerated engraftment of platelets and neutrophils is seen with IL-3 also after bone marrow transplantation. The effect on neutrophil recovery can be enhanced by the use of a myeloid growth factor such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or granulocyte (G)-CSF after five to 10 days of IL-3. Treatment enhancement is related to the effect of IL-3 on the proliferation of hematopoietic progenitors, which leads to an increase in target cells for GM- or G-CSF. Because of the increase in bone marrow proliferation, IL-3 is being used to increase the mobilization of progenitor cells to the blood and in bone marrow failure.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1066-5099
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
241-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7696963-Antineoplastic Agents,
pubmed-meshheading:7696963-Bone Marrow Diseases,
pubmed-meshheading:7696963-Bone Marrow Transplantation,
pubmed-meshheading:7696963-Clinical Trials as Topic,
pubmed-meshheading:7696963-Cytokines,
pubmed-meshheading:7696963-Hematopoiesis,
pubmed-meshheading:7696963-Humans,
pubmed-meshheading:7696963-Interleukin-3,
pubmed-meshheading:7696963-Neoplasms,
pubmed-meshheading:7696963-Neutropenia
|
pubmed:year |
1994
|
pubmed:articleTitle |
Present and future clinical relevance of interleukin 3.
|
pubmed:affiliation |
Sandoz Pharma Ltd., Basel, Switzerland.
|
pubmed:publicationType |
Journal Article,
Review
|